INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.

VIRUS GENES is an esteemed journal published by Springer, dedicated to advancing our understanding of virology and its related fields, including genetics, molecular biology, and immunology. With a publication history that spans from 1987 to 2024, this journal provides researchers and professionals with a platform to disseminate high-quality, peer-reviewed articles that explore the intricacies of viral genetics and their implications in health and disease. With an impact factor placing it in the Q3 quartile across multiple categories in 2023, including Genetics and Virology, VIRUS GENES serves as a crucial resource for academics seeking to stay at the forefront of viral research. Its commitment to showcasing innovative research makes it an invaluable asset for students and professionals aiming to deepen their knowledge in the rapidly evolving landscape of virology. Although currently not offering Open Access, the journal ensures wide accessibility through institutional subscriptions, thereby playing a vital role in the collaboration between scientists globally.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

Viruses-Basel, published by MDPI, is a leading interdisciplinary journal focused on the field of virology and infectious diseases, offering a platform for the rapid dissemination of high-quality research. Established in 2009, this open access journal has become an essential resource for researchers and health professionals, ensuring that critical findings are readily available to a global audience. With an impressive Q1 ranking in Infectious Diseases and a Q2 ranking in Virology as of 2023, the journal reflects its commitment to impactful research, validated by its notable positions within Scopus categories—ranked #84 out of 344 in Medicine: Infectious Diseases and #27 out of 80 in Immunology and Microbiology: Virology. The journal adheres to high standards of academic rigor, and by embracing an open access model, it promotes unrestricted access to scientific knowledge, fostering collaboration among researchers, professionals, and students alike. Situated in Basel, Switzerland, the journal serves as a cornerstone in the dissemination of research findings related to viral diseases and their implications on public health.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.